Sponsor:
Amgen
Code:
NCT07908641
Conditions
Psoriasis
Arthritis, Psoriatic
Oral Ulcer
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Accepted
Interventions
Apremilast XR
Apremilast IR
Brief summary:
Conditions
Psoriasis
Arthritis, Psoriatic
Oral Ulcer
Study ID
NCT07908641
Start date
Nov 18, 2026
Status verified date
Nov, 2026
Completion date
Jan 10, 2027
Anticipated
Primary completion date
Jan 10, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Accepted
Enrollment
114 participants
Anticipated
Allocation
Randomized
Intervention Model
Crossover
Primary purpose
Basic Science
Arms
experimental: Treatment Sequence AB
active comparator: Treatment Sequence BA
Interventions
Apremilast XR
Apremilast IR
Primary outcome measure
Central contacts
Locations
Fortrea Clinical Research Unit - Daytona Beach
Recruiting
Daytona Beach, Florida, United States, 32117-5116
Fortrea Clinical Research Unit - Dallas
Recruiting
Dallas, Texas, United States, 75247-4968
Sponsor
Amgen
Last update posted
Nov 20, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Amgen on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.